erlotinib hydrochloride has been researched along with Dermatoses in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (23.53) | 29.6817 |
| 2010's | 8 (47.06) | 24.3611 |
| 2020's | 5 (29.41) | 2.80 |
| Authors | Studies |
|---|---|
| Li, J; Yin, R; Yu, Y; Zou, Y | 1 |
| Dai, X; Fu, H; Lin, J; Wang, Y; Zhao, Q; Zheng, Y; Zhu, C | 1 |
| Chen, Y; Huang, M; Jiang, X; Liu, Y; Xing, H; Yu, S | 1 |
| Ikarashi, N; Kamei, J; Kaneko, M; Kon, R; Sakai, H; Takayama, N; Tanaka, R; Watanabe, T; Yokoyama, T; Yoshino, M | 1 |
| Abd-Rabu, R; Ding, J; Dunnack, H; Farah, MH; Ginex, PK; Hasan, B; Malandris, K; Manolopoulos, A; Morgan, RL; Murad, MH; Nayfeh, T; Prokop, L; Rajjoub, M | 1 |
| Cheng, X; Han, J; He, J; Huang, W; Xiong, C; Zhu, H; Zhu, Z | 1 |
| Ezzedine, K | 1 |
| Bal, C; Gupta, RK; Kumar, K; Kumar, R; Singh, H | 1 |
| Belum, VR; Bölke, E; Buhren, BA; Gerber, PA; Hevezi, P; Homey, B; Jänicke, RU; Lacouture, ME; Robert, C; Schrumpf, H; Sohn, D | 1 |
| Bekers, O; Heideman, DA; Lind, JS; Postmus, PE; Smit, EF; Thunnissen, EB | 1 |
| Fujita, S; Fukuhara, A; Hatachi, Y; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Honma, M; Suzuki, H; Yamamoto, N | 1 |
| Suzuki, Y; Yamamoto, T | 1 |
| Guo, Z; Li, J | 1 |
| Basti, S; Benson, A; Lacouture, ME; Patel, J | 1 |
| Gross, GE; Schäd, SG; Zoller, A | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
3 review(s) available for erlotinib hydrochloride and Dermatoses
| Article | Year |
|---|---|
Targeted Therapy- and Chemotherapy-Associated Skin Toxicities: Systematic Review and Meta-Analysis.
Topics: Erlotinib Hydrochloride; Humans; Skin Diseases | 2020 |
[What's new in dermatological therapy?]
Topics: Adalimumab; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Dermatologic Agents; Dermatology; Erlotinib Hydrochloride; Herpes Zoster Vaccine; Humans; Interleukin 1 Receptor Antagonist Protein; Isotretinoin; Piperidines; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Skin Diseases; Trimethoprim, Sulfamethoxazole Drug Combination | 2016 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
14 other study(ies) available for erlotinib hydrochloride and Dermatoses
| Article | Year |
|---|---|
5-aminolevulinic acid-mediated photodynamic therapy (ALA-PDT) for acneform rash induced by erlotinib: A case report.
Topics: Acne Vulgaris; Aminolevulinic Acid; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Humans; Lung Neoplasms; Photochemotherapy; Photosensitizing Agents; Skin Diseases | 2022 |
Xijiao Dihuang decoction relieves the erlotinib-induced dermatitis.
Topics: Animals; Chemokines; Cytokines; Dermatitis; Erlotinib Hydrochloride; Mice; Mice, Nude; Molecular Docking Simulation; Neoplasms; Quality of Life; Skin Diseases | 2023 |
Network pharmacology-based preventive effect of XZF on cutaneous toxicities induced by EGFR inhibitor.
Topics: Animals; Drugs, Chinese Herbal; ErbB Receptors; Erlotinib Hydrochloride; Female; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Signal Transduction; Skin; Skin Diseases | 2020 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib Induces Dry Skin via Decreased in Aquaporin-3 Expression.
Topics: Animals; Aquaporin 3; Cell Line; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gene Expression Regulation; Humans; Male; Mice; Phosphorylation; Protein Kinase Inhibitors; Skin; Skin Diseases; Water | 2020 |
Common and uncommon adverse cutaneous reactions to erlotinib: a study of 20 Chinese patients with cancer.
Topics: Adult; Aged; Anaphylaxis; Antineoplastic Agents; Asian People; Erlotinib Hydrochloride; Female; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Skin Diseases | 2018 |
Erlotinib-induced cutaneous toxicity: findings on 18F-FDG PET/CT imaging.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fluorodeoxyglucose F18; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Skin Diseases; Tomography, X-Ray Computed | 2015 |
Mechanisms of skin aging induced by EGFR inhibitors.
Topics: Aged; Aged, 80 and over; Aging; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Retrospective Studies; Skin Aging; Skin Diseases | 2016 |
Dramatic response to low-dose erlotinib of epidermal growth factor receptor mutation-positive recurrent non-small cell lung cancer after severe cutaneous toxicity.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2009 |
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver Function Tests; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Population Groups; Quinazolines; Retrospective Studies; Skin Diseases; Treatment Failure | 2011 |
Off-target serine/threonine kinase 10 inhibition by erlotinib enhances lymphocytic activity leading to severe skin disorders.
Topics: Base Sequence; Cell Line; Chromatography, Liquid; Erlotinib Hydrochloride; Humans; Jurkat Cells; Lymphocytes; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; RNA, Small Interfering; Skin Diseases; Tandem Mass Spectrometry | 2011 |
Reactive perforating collagenosis during erlotinib therapy.
Topics: Aged; Collagen Diseases; Diabetes Complications; Drug Eruptions; Erlotinib Hydrochloride; Humans; Male; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
The SERIES clinic: an interdisciplinary approach to the management of toxicities of EGFR inhibitors.
Topics: Algorithms; Anti-Bacterial Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatologic Agents; Dermatology; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Eye Diseases; Female; Humans; Interprofessional Relations; Lung Neoplasms; Medical Oncology; Middle Aged; Ophthalmology; Quinazolines; Referral and Consultation; Skin Diseases; Tacrolimus | 2006 |
Erlotinib-associated skin reactions - case report and proposal for classification.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Skin Diseases | 2006 |